Columbia Pacific CCO – Notice of Data Event
PORTLAND, Ore., Dec. 26, 2025 /PRNewswire/ -- On or about October 27, 2025, Columbia Pacific CCO learned that one or more people...
Medicaid
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert...
2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement
Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed operating models, tightening third- and...
Best Peptides for Muscle Growth: Prescription Sermorelin Access, Injectable vs. Dissolving Tablets, and Realistic Expectations
Platform Analysis: Injectable vs. Dissolving Tablet Formats, Prescription Requirements, Monthly Subscription Costs, and Timeline Expectations for Growth Hormone Secretagogue TherapyAUSTIN,...
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23,...
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and...
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total...
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved...
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our",...
Netsmart Strengthens Interoperability Leadership Through CMS Health Technology Ecosystem Pledge
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based care providers, announced its commitment...
Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / December 22, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation"...
Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season
Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as 100,000+ Patients Seek Affordable Semaglutide...
WebPT Announces Advocate Physical Therapy and Tilton’s Therapy as Winners of the 2025 Ascend Awards
Practice of the Year and Innovator of the Year honorees recognized for patient-centered care, operational excellence, and forward-thinking leadershipPHOENIX, Dec....
NHI Announces $89.2 Million in Investments and Updates Pipeline
MURFREESBORO, TN / ACCESS Newswire / December 18, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it has...
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority...
ZeOmega Recognized in 2025 Gartner(R) Market Guide for U.S. Healthcare Payer Care Management Workflow Applications
ZeOmega believes that this designation underscores its differentiation in modernizing payer care management amid rising interoperability and AI-related regulatory demands...
ID.me Announces Contract with CMS to Advance Access, Security, and User Experience on Medicare.gov
MCLEAN, Va., Dec. 16, 2025 /PRNewswire/ -- ID.me today announced it has entered into a contract with the Centers for Medicare...
ID.me Announces Contract with CMS to Advance Access, Security, and User Experience on Medicare.gov
MCLEAN, Va., Dec. 16, 2025 /PRNewswire/ -- ID.me today announced it has entered into a contract with the Centers for Medicare...